Cubist Systematic Strategies, LLC Ocugen, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.36 - $0.57 $17,282 - $27,364	-48,008 Reduced 15.31%	265,469 $151,000
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.62 $17,952 - $27,825	-44,880 Reduced 12.52%	313,477 $125,000
Q2 2023 Aug 14, 2023	BUY	$0.45 - $0.88 $80,658 - $157,732	179,242 Added 100.07%	358,357 $193,000
Q1 2023 May 15, 2023	BUY	$0.82 - $1.33 $146,874 - $238,222	179,115 New	179,115 $152,000
Q3 2022 Nov 14, 2022	SELL	$1.75 - $3.1 $80,769 - $143,077	-46,154 Reduced 99.47%	248 $0
Q2 2022 Aug 15, 2022	BUY	$1.83 - $3.45 $55,275 - $104,207	30,205 Added 186.49%	46,402 $105,000
Q1 2022 May 16, 2022	SELL	$2.34 - $4.72 $26,743 - $53,944	-11,429 Reduced 41.37%	16,197 $53,000
Q4 2021 Feb 14, 2022	BUY	$4.38 - $15.67 $121,001 - $432,899	27,626 New	27,626 $126,000
Q3 2021 Nov 15, 2021	SELL	$6.36 - $8.51 $410,563 - $549,354	-64,554 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$5.52 - $15.68 $946,332 - $2.69 Million	-171,437 Reduced 72.65%	64,554 $518,000
Q1 2021 May 17, 2021	BUY	$1.66 - $15.81 $391,745 - $3.73 Million	235,991 New	235,991 $1.6 Million

125

78.4M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $156M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.